Profiling the Expression of Circulating Acute-Phase Proteins, Cytokines, and Checkpoint Proteins in Patients with Severe Trauma: A Pilot Study.

PURPOSE: Severe trauma may lead to the systemic release of inflammatory mediators into the circulation with profound acute-phase responses; however, the understanding of the expression of these mediators remains limited. This study aimed to characterize the alterations in the expression of circulating acute-phase proteins, cytokines, and checkpoint proteins in patients with severe trauma injuries. PATIENTS AND METHODS: The study population included trauma patients in the intensive care unit (ICU) with an injury severity score equal to or greater than 16 and who had used a ventilator for 48 hours. A total of 12 female and 28 male patients were recruited for the study; six patients died and 34 survived. Blood samples collected at acute stages were compared with those drawn at the subacute stage, the time when the patients were discharged from the ICU, or before the discharge of the patients from the hospital.
RESULTS: The study identified that the expression of acute-phase proteins, such as alpha-1-acid glycoprotein and C-reactive protein, and cytokines, including granulocyte colony-stimulating factor, interleukin-6, and interleukin-1 receptor antagonist, was elevated in the circulation after severe trauma. In contrast, the levels of acute-phase proteins, such as alpha-2-macroglobulin, serum amyloid P, and von Willebrand factor, and cytokines, including interleukin-4 and interferon gamma-induced protein 10, were reduced. However, there were no significant differences in the expression of checkpoint proteins in the circulation.
CONCLUSION: The dysregulated proteins identified in this study may serve as potential therapeutic targets or biomarkers for treating patients with severe trauma. However, the related biological functions of these dysregulated factors require further investigation to validate their functions.

Introduction

Tissue damage during trauma results in the release of damage-associated molecular patterns and other mediators at the site of injury. Such mediators disrupt the homeostasis of the immune system and may activate various immune responses with downstream complications, such as infections and sepsis. To adapt and survive, hosts react with a set of mechanisms aimed at restoring the equilibrium of the immune system. The acute phase response of the innate immune system plays a crucial role in trauma1 and is demonstrated by the change in circulating acute-phase protein levels; this may explain the differences in susceptibility to infectious organisms.2 The systemic acute phase response might impair host defense against P. aeruginosa pneumonia3 and inhibit the local inflammatory response to A. baumannii pneumonia, thereby facilitating the outgrowth of bacteria.4

Trauma leads to the systemic release of inflammatory mediators into the circulation from norepinephrine terminals in peripheral organs such as the liver, spleen, and lymphocytes.5,6 These cytokines from severely injured trauma patients systemically regulate cytokine expression in the bone marrow stroma,7 resulting in the prolonged mobilization of hematopoietic progenitor cells from the bone marrow stroma8 into the circulation and to the site of injury.9–11 These cytokines are involved in the early systemic inflammatory response as well as in the compensatory anti-inflammatory response that occurs later. An imbalance in these responses is responsible for the development of sepsis or multiple organ failure.12,13 In addition to the participation of these cytokines in inflammatory processes, they are also the chief stimulators of acute-phase proteins.14

The balance of the immune system is controlled by checkpoint regulators in the body. The checkpoint regulators are membrane-bound proteins that serve as a secondary signal to direct the immune response to a particular antigen.15 In the absence of such signals, the immune response is neither activated nor attenuated.15 After the modification of the immune response over time, these checkpoint regulators enable the unique response of immune cells to various environmental conditions.16 For example, after burn injury, anti-programmed cell death ligand-1 (anti-PD-L1) effectively increases bacterial clearance, protects against multiple organ failure, and improves survival following systemic S. aureus infection.17 In addition, activation of the PD-1/PD-L1 pathway with PD-L1 protein significantly attenuates inflammatory responses and brain edema in the treatment of surgical brain injury.18,19

Although patients who succumb to severe injuries are known to have profoundly different inflammatory and acute-phase responses, the understanding of these processes remains limited.20 There is also a lack of information on the expression of immune checkpoint proteins following severe traumatic injury. Cytokines and cytokine receptors operate together with the produced acute-phase proteins in a cascade effect to influence the pathophysiological response of the body following trauma.1 Therefore, the characterization of these proteins may help in the identification of therapeutic targets or biomarkers for patients with severe trauma. Accordingly, the present study aimed to characterize the alterations in the expression of circulating acute-phase proteins, cytokines, and checkpoint proteins in patients who experienced severe trauma.

Patients and Methods

Patients Enrollment

Only patients who satisfied the following three conditions were included in this study: (1) adult trauma patients aged 20 years and above who were admitted to the trauma ICU, (2) patients with an injury severity score (ISS) equal to or greater than 16, indicating severe injury;21–23 and (3) the use of ventilator support for more than 48 h. Exclusion criteria included patients with cancer, those who were immunocompromised, or were not willing to be involved in this study. Finally, 40 critical adult trauma patients admitted to the hospital between December 2017 and December 2018 were enrolled in this study. This prospective study was approved by the institutional review board of the hospital. All patients signed a written consent before blood sample collection.

Clinical Data and Specimen Collection

The medical information of patients was collected from the Trauma Registry System of the hospital24–26 and included sex, age, pre-existing comorbidities, abbreviated injury scale (AIS) in different body regions, ISS, period of ventilator use, and final condition (mortality or survival). From the medical charts, the vital signs, including temperature, systolic blood pressure (SBP), heart rate (HR), and respiratory rate (RR) at the time of blood collection were recorded with the laboratory data, including white blood cell (WBC) and platelet counts, and hematocrit (Hct), sodium (Na), potassium (K), blood urine nitrogen (BUN), creatinine (Cr), aspartate aminotransferase (AST), and bilirubin levels. The Revised Trauma Score (RTS) was calculated by taking the weighted sum of 0.9368 × Glasgow Coma Scale (GCS) score + 0.7326 × SBP + 0.2908 × RR.27 The trauma and injury severity score (TRISS) was calculated based on a logarithmic regression equation: survival probability = 1/(1+ e-b), where b (penetrating injury) = −2.5355 + 0.9934 × RTS - 0.0651 × ISS - 1.1360 × Age(index) and b (blunt injury) = −0.4499 + 0.8085 × RTS - 0.0835 × ISS - 1.7430 × Age(index). In the formula, age (index) is awarded 1, where patients above 55 and patients below and of 55 are awarded 0.27 When the patients were admitted to the trauma ICU and had used a ventilator for 48 h, peripheral blood samples were collected prospectively after this time point but within 72 h after admission into the ICU. The blood samples drawn at this time point are indicated as acute-stage samples. Another peripheral blood sample from the same patient population was drawn from the patients in the ward just before discharge from the hospital, after they had left the ICU. The blood samples drawn at this time point are indicated as subacute-stage samples. A second blood sample was not drawn from patients who died in the ICU. Ten mL of the fasting blood was drawn from the veins of the forearm. Serum was obtained from peripheral blood samples using Becton Dickinson Serum Separator Tubes (BD Vacutainer® SST™ Tube, BD Diagnostics, Franklin Lakes, NJ) with no additives, centrifuged, collected, aliquoted, and immediately frozen at −80 °C until use.

Multiplex Enzyme-Linked Immunosorbent Assay (ELISA)

Serum protein expression was measured using the Multiplex platform (Luminex system, Millipore, MA) for ELISA with panels of human acute-phase proteins (human cardiovascular panel 3, Cat. No. HCVD3MAG-67K), human cytokines, and chemokines (human cytokine/chemokine panel I, Cat. No. HCYTOMAG-60K), and human checkpoint protein (human immune checkpoint protein, Cat. No. HCKPMAG-11K) in duplicate for each patient sample, according to the manufacturer’s protocol. The inter- and intra-assay percentages of the coefficients of variability (%CV) are listed in .

The acute-phase proteins included alpha-2-macroglobulin (A2M), alpha-1-acid glycoprotein (AGP), adipsin/factor D, C-reactive protein (CRP), fetuin-A, fibrinogen, haptoglobin, sL-selectin, platelet factor 4 (PF4), serum amyloid P (SAP), and von Willebrand factor (vWF). The concentration of serum proteins was expressed in pg/mL.

The cytokines and chemokines included soluble CD40 ligand (sCD40L), epidermal growth factor (EGF), eotaxin, fibroblast growth factor 2 (FGF-2), FMS-like tyrosine kinase 3 (FLT3) ligand, fractalkine, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), growth-related oncogene (GRO), interferon α2 (IFN-α2), IFNγ, interleukin (IL)-1α, IL-1β, IL-1RA, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17A, interferon gamma-induced protein 10 (IP-10), monocyte chemotactic protein 1 (MCP-1), MCP-3, macrophage-derived chemokine (MDC), macrophage inflammatory protein 1α (MIP-1α), MIP-1β, platelet-derived growth factor (PDGF)-AA, PDGF-AB/BB, RANTES, tumor necrosis factor α (TNF-α), TNF-β, and vascular endothelial growth factor (VEGF)-A.

The checkpoint proteins include B- and T-lymphocyte attenuator (BTLA), cluster of differentiation (CD)27, CD28, CD40, CD80, CD86, cytotoxic T-lymphocyte antigen 4 (CTLA-4), glucocorticoid-induced TNFR-related protein (GITR), glucocorticoid-induced TNFR-related protein ligand (GITRL), herpes virus entry mediator (HVEM), inducible T-cell co-stimulator (ICOS), lymphocyte-activation protein 3 (LAG-3), programmed cell death 1 (PD-1), programmed cell death ligand 1 (PD-L1), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), and Toll-like receptor 2 (TLR2).

Statistical Analysis

Data were analyzed using Windows version 23.0 (IBM Inc., Chicago, IL, USA). Two-sided Fisher’s exact or Pearson’s chi-squared (χ2) tests were used to compare categorical data. Continuous data were analyzed using the non-parametric Mann–Whitney U-test. Pearson’s correlation coefficient analysis was carried out to measure the correlation between patient characteristics and differentially expressed protein targets at the acute and subacute stages. Continuous data are expressed as the median and interquartile range (IQR, Q1–Q3). Statistical significance was indicated by two-sided p values < 0.05.

Results

Patient Characteristics

The enrolled patients included 12 female and 28 male patients with an average age of 56.3 ± 18.4 years (mini-max 22–84 years). During the study, six patients died, and 34 survived. For surviving patients, the time between the first (acute stage) and second (subacute stage) blood sample collection was 21.1 ± 8.9 days. As shown in Table 1, there were no significant differences in the age and prevalence of sex or pre-existing comorbidities between the survival and death groups. In these two groups, there were no significant differences in vital signs and laboratory data. No significant difference was also found between the death and survival of patients with AIS in different body regions, ISS, RTS, or TRISS.

Table 1

Characteristics of Patients in the Survival and Death Groups

Variables	Survival n = 34	Death n = 6	P-value
Age (years)	56.5 [37.5, 65.5]	68.0 [59.8, 80.0]	0.072
Gender
Male, n (%)	24 (70.6)	4 (66.7)	>0.999
Female, n (%)	10 (29.4)	2 (33.3)
Co-morbidities
DM, n (%)	6 (17.6)	0 (0.0)	0.565
HTN, n (%)	9 (26.5)	4 (66.7)	0.075
CAD, n (%)	3 (8.8)	1 (16.7)	0.493
CVA, n (%)	1 (2.9)	1 (16.7)	0.281
AIS (head/neck)			0.835
0	6 (17.6)	1 (16.7)
2	2 (5.9)	0 (0.0)
3	2 (5.9)	0 (0.0)
4	14 (41.2)	2 (33.3)
5	10 (29.4)	3 (50.0)
AIS (face)			0.473
0	27 (79.4)	6 (100.0)
1	1 (2.9)	0 (0.0)
2	6 (17.6)	0 (0.0)
AIS (thorax)			0.867
0	23 (67.6)	4 (66.7)
1	1 (2.9)	0 (0.0)
3	8 (23.5)	2 (33.3)
4	2 (5.9)	0 (0.0)
AIS (abdomen)			0.623
0	26 (76.5)	6 (100.0)
3	2 (5.9)	0 (0.0)
4	4 (11.8)	0 (0.0)
5	2 (5.9)	0 (0.0)
AIS (extremity)			0.779
0	20 (58.8)	5 (83.3)
1	1 (2.9)	0 (0.0)
2	7 (20.6)	1 (16.7)
3	5 (14.7)	0 (0.0)
4	1 (2.9)	0 (0.0)
Temperature (oC)	36.5 [36.0, 37.3]	36.6 [36.0, 37.3]	0.594
SBP (mmHg)	142.0 [112.8, 163.8]	140.0 [106.5, 152.5]	0.691
Heart rate (times/min)	93.5 [75.0, 112.5]	86.0 [85.0, 117.8]	0.955
Respiratory rate (times/min)	20.0 [18.0, 21.8]	19.0 [18.0, 23.0]	0.893
WBC (103/uL)	11.9 [9.7, 14.6]	10.3 [8.9, 14.3]	0.677
Hct (%)	41.1 [37.3, 44.7]	40.8 [37.3, 43.9]	0.910
Platelet (103/uL)	208.0 [189.5, 232.5]	206.0 [174.8, 256.8]	0.850
Na (mEq/L)	138.0 [135.3, 139.8]	137.5 [135.3, 139.8]	0.717
K (mEq/L)	3.7 [3.2, 3.9]	3.1 [2.7, 3.6]	0.119
BUN (mg/dL)	16.0 [12.0, 19.8]	17.5 [15.3, 22.0]	0.426
Cr (mg/dL)	0.9 [0.8, 1.3]	1.0 [0.9, 1.2]	0.705
AST	44.5 [32.0, 95.5]	66.0 [49.5, 138.0]	0.272
Bilirubin (mg/dL)	0.9 [0.6, 1.0]	1.1 [0.9, 1.3]	0.164
ISS	24.5 [18.5, 25.0]	20.5 [16.0, 31.8]	0.552
RTS	6.6 [5.8, 7.4]	5.5 [5.1, 6.3]	0.258
TRISS	0.85 [0.64, 0.95]	0.83 [0.40, 0.88]	0.437

Note: The data are expressed as n (%) or median with IQR [Q1–Q3].

Abbreviations: AIS, Abbreviated Injury Scale; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CAD, coronary artery disease; CI, confidence interval; CVA, cerebral vascular accident; DM, diabetes mellitus; Hct, hematocrit; HTN, hypertension; IQR, interquartile range; ISS, injury severity score; K, potassium; Na, sodium; RTS, Revised Trauma Score; TRISS, New Trauma and Injury Severity Score; WBC, white blood cells.

Expression of the Acute Phase Proteins

There was no significant difference in the acute-phase proteins of acute-stage serum samples between survival (n = 34) and death (n = 6). The acute-stage serum concentrations of AGP (P  =  0.001) and CRP (P <  0.001) were significantly higher than those in the subacute-stage serum (Table 2 and Figure 1). The elevation of CRP in the acute stage of either survival or even death was approximately 3-fold higher than that in the subacute stage. Conversely, the acute-stage serum concentrations of A2M (P  =  0.002), SAP (P  =  0.006), and vWF (P  =  0.018) in the surviving patients (n = 34) were significantly lower than those in the subacute-stage serum.

Table 2

Expression of the Acute Phase Proteins in the Acute-Stage and Subacute-Stage Serum Samples

Variables	Acute Stage		Subacute Stage	#1 P	#2 P
	Survival n = 34	Death n = 6	Survival n = 34
A2M	821,565 (279,981)	1,050,820 (371,744)	993,596 (254,318)	0.099	0.002
Adipsin	5270 (5735)	5138 (2306)	5107 (5749)	0.256	0.213
AGP	2,810,213 (1,175,978)	2,897,929(1,224,919)	2,054,879 (626,089)	0.895	0.001
CRP	360,253 (146,016)	378,844 (192,584)	124,470 (127,898)	0.636	<0.001
CXCL4	1000 (1671)	969 (1130)	1248 (1791)	0.647	0.236
Fetuin A	148,099 (85,979)	123,914 (19,340)	133,187 (69,341)	0.925	0.504
Fibrinogen	594,995 (243,066)	601,345 (69,059)	539,928 (154,057)	0.609	0.094
Haptoglobin	1,417,150 (985,468)	1,988,356 (662,764)	1,360,112 (1,174,957)	0.175	0.559
sL-Selectin	572 (256)	557(124)	683 (239)	0.583	0.062
SAP	11,969 (6243)	110,010 (4965)	15,628 (7458)	0.895	0.006
vWF	21,461 (12,118)	24,547 (16,434)	31,892 (21,588)	0.691	0.018

Notes: #1, comparison between surviving and dead patients in the acute stage; #2, comparison between surviving patients in the acute and subacute stages. The concentration of serum proteins is expressed in pg/mL.

Abbreviations: A2M, α-2-Macroglobulin; AGP, α-1-Acid glycoprotein; CRP, C-reactive protein.

Figure 1

Circulating acute-phase proteins and cytokines with significantly different expression in the acute-stage and subacute-stage serum samples of the surviving patients.

Expression of the Cytokines and Chemokines

The acute-stage serum concentrations of G-CSF and IL-6 in the patients who died were significantly higher than those in the acute-stage serum of the surviving patients (Table 3 and Figure 2). Among patients who died, the elevation of G-CSF and IL-6 in the acute stage was 5-fold (P  = 0.008) and 6-fold (P  =  0.013), respectively, compared to those of the surviving patients. The acute-stage serum concentrations of G-CSF and IL-6 in surviving patients were 3-fold (P  =  0.014) and 6-fold (P  <  0.001) higher, respectively, than those in the subacute stage. The acute-stage serum concentrations of IL-1RA (P  =  0.013) were significantly higher than those in the subacute-stage serum. In contrast, the acute-stage serum concentrations of IL-4 (P  =  0.017) and IP-10 (P =  0.006) were significantly lower than those in the subacute-stage serum (Table 3 and Figure 1).

Table 3

Expression of the Cytokines and Chemokines in the Acute-Stage and Subacute-Stage Serum Samples

Variables	Acute Stage		Subacute Stage	#1 P	#2 P
	Survival n = 34	Death n = 6	Survival n = 34
EGF	6.88 (8.99)	4.11 (2.22)	11.49 (21.73)	0.679	0.522
Eotaxin	66.31 (36.88)	57.66 (10.04)	73.25 (51.68)	0.925	0.615
FGF-2	61.20 (50.32)	53.48 (29.47)	57.22 (47.32)	0.880	0.883
Flt3 Ligand	9.02 (19.59)	3.20 (0.00)	11.90 (25.34)	0.072	0.714
Fractalkine	71.92 (285.23)	34.32 (24.05)	58.23 (206.74)	0.149	0.487
G-CSF	65.63 (102.74)	311.67 (268.99)	22.85 (47.31)	0.008	0.014
GM-CSF	6.65 (4.30)	7.01 (4.33)	8.34 (8.16)	0.789	0.656
GRO	253.50 (255.26)	210.90 (158.34)	404.26 (360.27)	0.748	0.138
IFNα2	15.01 (23.51)	17.67 (11.34)	15.85 (13.70)	0.227	0.127
IFNγ	14.05 (14.25)	6.11 (2.84)	15.79 (20.67)	0.280	0.615
IL-1RA	64.82 (100.69)	120.42 (125.44)	26.14 (34.11)	0.218	0.013
IL-1α	16.08 (20.31)	19.16 (24.18)	41.79 (81.35)	0.875	0.077
IL-1β	3.83 (3.66)	3.64 (1.08)	4.96 (5.96)	0.561	0.152
IL-2	3.69 (1.73)	3.20 (0.00)	4.40 (4.83)	0.081	0.544
IL-3	3.26 (0.33)	3.20 (0.00)	3.20 (0.00)	0.057	0.167
IL-4	9.55 (8.91)	8.54 (4.29)	34.15 (46.77)	0.922	0.017
IL-5	3.47 (1.13)	3.71 (1.24)	3.49 (1.17)	0.717	0.762
IL-6	63.79 (107.17)	380.26 (782.47)	10.29 (11.22)	0.013	<0.001
IL-7	6.76 (12.70)	4.05 (2.01)	5.76 (14.08)	0.407	0.654
IL-8	9.31 (12.09)	11.75 (14.01)	5.38 (3.55)	0.772	0.054
IL-9	3.20 (0.00)	3.20 (0.00)	3.15 (0.29)	0.176	1.000
IL-10	28.23 (62.96)	28.78 (29.44)	18.82 (51.26)	0.894	0.051
IL-12 (p40)	3.92 (2.49)	4.31 (2.71)	7.83 (17.12)	0.855	0.495
IL-12 (p70)	7.58 (15.97)	3.83 (0.99)	8.10 (23.93)	0.455	0.230
IL-13	3.38 (0.68)	4.31 (2.72)	6.56 (11.87)	0.513	0.921
IL-15	4.97 (1.86)	4.28 (1.58)	3.78 (1.48)	0.471	0.352
IL-17A	10.88 (11.17)	3.83 (1.37)	9.35 (11.29)	0.249	0.202
IP-10	665.43 (654.66)	837.46 (883.24)	1194.04 (1016.73)	0.925	0.006
MCP-1	606.00 (857.73)	1287.40 (2169.67)	358.61 (296.53)	0.748	0.069
MCP-3	7.72 (8.44)	5.56 (3.59)	10.35 (23.09)	0.516	0.478
MDC	293.65 (131.59)	251.75 (168.99)	390.28 (326.88)	0.507	0.150
MIP-1α	4.80 (3.08)	5.67 (3.95)	4.95 (3.41)	0.486	1.000
MIP-1β	38.97 (33.73)	42.32 (15.18)	29.67 (27.17)	0.156	0.082
sCD40L	358.71 (1115.32)	71.88 (42.82)	187.68 (305.94)	0.179	0.213
TGFα	3.66 (1.71)	3.20 (0.00)	3.32 (0.70)	0.280	0.940
TNFα	23.87 (20.10)	29.41 (16.92)	21.70 (15.20)	0.140	0.844
TNFβ	4.06 (3.34)	3.47 (0.65)	6.65 (14.25)	0.663	0.714
VEGF	79.62 (91.55)	76.37 (79.77)	83.45 (103.23)	0.761	0.995

Notes: #1, comparison between surviving and dead patients in the acute stage; #2, comparison between surviving patients in the acute and subacute stages. The concentration of serum proteins is expressed in pg/mL.

Figure 2

Circulating cytokines with significantly different expression in the acute-stage serum samples of the surviving and dead patients.

Expression of the Checkpoint Proteins

There were no significant differences in the checkpoint proteins in the acute-stage serum samples between patients who survived and those who died. In addition, there were no significant differences in serum checkpoint proteins between the acute and subacute stage samples (Table 4).

Table 4

Expression of the Checkpoint Proteins in the Acute-Stage and Subacute-Stage Serum Samples

Variables	Acute Stage		Subacute Stage	#1 P	#2 P
	Survival n = 34	Death n = 6	Survival n = 34
BTLA	1366 (1778)	1666 (1749)	1287 (1550)	0.557	0.713
CD27	8116 (12,323)	10,150 (5563)	7601 (18,287)	0.078	0.312
CD28	9457 (11,003)	11,410 (10,557)	8557 (9425)	0.449	0.917
CD40	884 (1611)	1061 (712)	1110 (2609)	0.092	0.339
CD80/B7-1	265 (337)	344 (412)	249 (288)	0.691	0.504
CD86/B7-2	1719 (2120)	2291 (2498)	1919 (1959)	0.609	0.194
CTLA-4	153 (263)	207 (308)	204 (258)	0.746	0.422
GITR	231 (458)	283 (516)	291 (407)	0.835	0.086
GITRL	580 (681)	735 (835)	713 (664)	0.880	0.087
HVEM	3567 (5185)	5004 (3528)	3277 (5257)	0.072	0.937
ICOS	1184 (1652)	1375 (1642)	1182 (1364)	0.438	0.139
LAG-3	34,676 (34,291)	45,725 (39,062)	32,732 (26,711)	0.719	0.544
PD-1	1474 (2178)	1893 (2307)	1749 (2103)	0.460	0.083
PD-L1	141 (243)	176 (258)	166 (225)	0.472	0.054
TIM-3	6265 (7223)	9086 (8117)	567 (5442)	0.099	0.893
TLR-2	2420 (2659)	2772 (2713)	2227 (2441)	0.583	0.917

Notes: #1, comparison between surviving and dead patients in the acute stage; #2, comparison between surviving patients in the acute and subacute stages. The concentration of serum proteins is expressed in pg/mL.

Correlation Analysis

To attenuate the confounding effect of patient characteristics on the expression of circulating proteins. Pearson’s correlation analysis was performed to measure the correlation between patient characteristics and differentially expressed protein targets. The correlations with significant expression of at least a moderate correlation coefficient (r > 0.4) are shown in Figure 3. Specific attention would be focused on those markers that only had correlation at the acute stage but not at the subacute stage, that is, vWF and AST (r = 0.46), G-CSF and HTN (r = 0.41), RTS (r = −0.47), IL-6 and RR (r = 0.46), RTS (r = −0.43), and IP-10 and BUN (r = 0.54), and Cr (r = 0.40). No correlation of these significantly expressed markers with gender, AIS in different body regions, and ISS was found both in the acute and subacute stages.

Figure 3

Correlation of the differentially expressed circulating proteins with patient characteristics in the first (acute stage) and second (subacute stage) measurement of the samples.

Discussion

The study revealed elevated levels of acute-phase proteins AGP and CRP but decreased levels of A2M, SAP, and vWF in the circulation of patients after severe trauma. In addition, the serum concentrations of cytokines G-CSF, IL-6, and IL-1RA were increased, and the levels of IL-4 and IP-10 decreased. However, there were no significant differences in the levels of checkpoint proteins in the circulation.

The expression of G-CSF and IL-6 following trauma has received increased research attention. G-CSF is a potent stimulator of hematopoietic mobilization in response to inflammatory stimuli and plays a pivotal role in the expansion and differentiation of neutrophils in the bone marrow and their subsequent release into the blood circulation.28 A significant positive correlation between injury severity and circulating levels of G-CSF was found in patients with trauma.7,29,30 Patients in shock would have a 75-fold increase in G-CSF levels compared to those in the control group.31 Trauma patients with burns or sepsis have a similar increase in circulating G-CSF levels.29,32 Elevated G-CSF levels result in early and sustained mobilization of hematopoietic progenitor cells into the periphery in patients with severe trauma.31 Therefore, G-CSF is likely to respond to abnormal erythropoiesis after trauma,31 in which the anemic state persists in the bone marrow and lasts for at least two weeks.33

In addition, G-CSF is required for bacterial clearance. During acute infection, G-CSF is detected in the blood, along with the release of proinflammatory cytokines.34 G-CSF is released by monocytes and macrophages upon activation by endotoxins during infection.35 Higher G-CSF levels were associated with a three-fold greater incidence of acquired pneumonia and sepsis in hospitals.31 Likewise, in this study, the serum concentrations of G-CSF and IL-6 in patients who died were significantly higher than those in the surviving patients. Notably, depletion of endogenous G-CSF in vivo would make the animal more susceptible to experimental peritonitis than the control36 and lack of G-CSF was associated with a higher rate of sepsis.37 A clinical trial has shown that G-CSF treatment in patients with septic shock is associated with a dramatic improvement in patient survival.38 In brief, the level of G-CSF correlated with the severity of the injury in trauma patients, and the increased G-CSF acts to encounter stress with the mobilization of hematopoietic progenitor cells into the periphery. Higher morbidity and mortality may be encountered if G-CSF activation is blocked.

After trauma, prolonged and excessive elevations of circulating IL-6 levels have been reported and are highly associated with complications and mortality in patients.39,40 IL-6 is primarily synthesized by bone marrow stromal fibroblasts33,41 which also participate in cytokine regulation.42,43 Hemorrhagic shock can induce elevation of IL-6 and TNF-α, both of which in turn mediate the endogenous production of G-CSF.44 After traumatic brain injury, IL-6 levels are elevated within hours of injury5,45 and up to 2.4-fold in three hours, 3.7-fold in 24 hours, and 7.9-fold on the fifth day compared to the control subjects.46 IL-6 stimulates B cells to produce antibodies and inhibits insulin action through modification of insulin receptor signaling, thus increasing hypermetabolic and insulin resistance in the liver and skeletal muscle.47 IL-6 is also responsible for the induction of acute-phase inflammatory responses via stimulation of the liver to produce acute-phase proteins.47 A higher serum level of IL-6 is associated with the development of post-traumatic stress symptoms following injury.48,49 In patients with severe injuries, this increase in IL-6 may persist longer.50 In a study of 472 blunt trauma survivors, IL-6 production was affected over seven days post-injury by MCP-1, MIG, and IP-10 in patients with severe ISS, MCP-1, and MIG in patients with moderate ISS, and MIG alone in patients with mild ISS.39 Similarly, higher IL-6 plasma levels in trauma patients tend to lead to complications or death.51

CRP is a sensitive marker for detecting the acute phase of inflammation. It has been reported that after trauma, blood CRP levels are markedly increased during all periods of observation.46 In this study, the elevation of CRP was approximately three-fold higher in the serum of the acute stage than in the subacute stage. A major function of CRP is to bind phosphocholine and thus recognize phospholipid constituents of damaged cells and that of foreign pathogens.7 The formation of these protein-ligand complexes would then be removed by mononuclear macrophages. Other pro-inflammatory effects of CRP include the induction of inflammatory cytokines and tissue factors in monocytes.1 CRP and SAP belong to the pentraxin family of proteins and are involved in the activation of the complement cascade.52 SAP is a physiological and functional counterpart of CRP in humans.53 During systemic inflammation, substantial induction of serum SAP was observed.53 SAP is also released into the circulation in correlation with its antimicrobial and anti-inflammatory activities.54,55 The primary pathophysiological function of SAP is to modulate nuclear antigens that are exposed to the extracellular environment due to apoptosis or necrosis.56

In addition to CRP and SAP, three other acute-phase proteins (AGP, A2M, and vWF) were dysregulated in the acute stage after traumatic injury. AGP levels in acute trauma patients have been shown to exceed normal levels.57 Administration of AGP was reported to significantly reduce neutrophil accumulation, lipid peroxidation, and edema formation during resuscitation against trauma-hemorrhagic shock.58 Decreased A2M was noted due to hemodilution by fluid treatment, first extravasation and accumulation of proteins at the wound site, and altered hepatic protein production.59 The severity of trauma and the extent of wound tissue induces a parallel decrease in both albumin and A2M.59 In addition, vWF plays an important role in both hemostasis and thrombosis. A decreased plasma level of vWF points to a bleeding disorder.60

In this study, the dysregulated cytokines included increased levels of IL-1RA and decreased levels of IL-4 and IP-10. IL-1 is an important mediator of inflammation and cardiovascular disease,43,61,62 and its activity is modulated by IL-1RA, which has been reported to increase in the plasma one day following trauma.63 Endogenous IL-1RA suppresses occlusive vascular responses to injuries, such as atherosclerosis and restenosis.64 The absence of IL-1RA promotes neointimal formation after injury in mice. Furthermore, it has been reported that IL-4 levels are significantly lower in orthopedic trauma patients than in controls.40 IL-4 has been suggested to be an anti-inflammatory cytokine and works with other regulatory cytokines such as TGF-β and IL-10 to reduce the severity of the inflammatory reaction.13 In addition, IP-10 has been reported to be suppressed during injury.65 Levels of IP-10 in the circulation were significantly lower in human blunt trauma nonsurvivors than in survivors.66 The signaling mechanism that controls IP-10 expression also plays an important role in injury-induced inflammation.66

Considering that the patient characteristics, such as age, sex, pre-existing comorbidities, and injured regions, may present a confounder’s effect on the expression of circulating proteins,67 correlation analysis was performed to inspect the relationships of the significantly expressed protein targets and various patient characteristics. The results revealed that there was no correlation of these significantly expressed proteins with gender, AIS in different body regions, and ISS both in the acute and subacute stages. Interestingly, in the acute stage, the expression of some circulating proteins is correlated with the underlying conditions of the patients, such as the correlation between vWF and liver disease,68 G-CSF and HTN,69 IL-6 and dyspnea,70 as well as IP-10 and acute kidney injury71 has been recognized in the literature. Moreover, because the calculation of RTS was based on GCS, SBP, and RR [27], the relationship between RTS and G-CSF, which was correlated with HTN, as well as IL-6, which was correlated with RR, can be recognized.

Cytokines and cytokine receptors operate both as a cascade and as a network to stimulate the production of acute-phase proteins.1 The effects of cytokines on target cells may be inhibited or enhanced by other cytokines, hormones, cytokine-receptor antagonists, and circulating receptors.7 In addition, these cells are most likely exposed and are influenced by a combination of mediators, regardless of acute-phase proteins or cytokines. The identified dysregulated proteins in this study may serve as potential therapeutic targets or biomarkers for treating patients with severe trauma. However, the related biological functions of these dysregulated factors require further investigation to validate their functions. Furthermore, the measurement of these identified significantly dysregulated circulating proteins in a large scale numbers of cohort of patients with severe trauma and patients with ISS scores less than 16 would provide more valuable information for exploring the role of these proteins. In this study, there were no significant differences in the expression of checkpoint proteins in the circulation. Immune checkpoints are a normal part of the immune system to prevent an overreactive immune response that destroys healthy cells.72 This study did not identify evidence of involvement of the surveillance system of immune checkpoints to combat the immune response of patients who sustained severe trauma. However, further measuring of the expression of immune checkpoint proteins in T cells or immune cells of patients is encouraged.

This study has some limitations. First, conditions such as resuscitation, damage control, surgical intervention, and even the use of drugs such as beta-blockers, antihypertensive drugs, and hypoglycemic drugs may lead to a bias. Second, the circulating proteins were dynamic in nature, and the conclusions drawn from a single measurement or two measurements may differ from those drawn from multiple measurements averaged over time. Further, the study population was relatively small to depict a complex network condition of these circulating proteins; thus, it can only serve as a pilot study. Finally, the population included in this study was limited to a single urban trauma center. However, the identified dysregulated proteins in this study may serve as potential therapeutic targets or biomarkers for treating patients with severe trauma, although the related biological functions of these dysregulated factors require further investigation to validate their function. Furthermore, the measurement of these identified significantly dysregulated circulating proteins in cohorts consisting of a large number of patients with severe trauma and patients with ISS scores less than 16 would provide more valuable information for exploring the role of these proteins.

Conclusion

The study identified that the levels of acute-phase proteins, such as AGP and CRP, and cytokines, such as G-CSF, IL-6, and IL-1RA, were elevated in the circulation after severe trauma, while the levels of acute-phase proteins, such as A2M, SAP, and vWF, and cytokines, including IL-4 and IP-10, were reduced. These identified dysregulated proteins may serve as potential therapeutic targets or biomarkers for treating patients with severe trauma.